SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”,HKEX: 01801), a world-class biopharmaceutical company that developsSAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”,HKEX: 01801), a world-class biopharmaceutical company that develops

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

2026/02/13 09:15
7 min read

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”,HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial is evaluating the company’s developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. IBI354 has two pivotal Phase 3 trials ongoing (HeriCare-Ovarian01, HeriCare-Breast01), which holds potential to deliver a new generation of ADC therapies characterized by “high potency and low-toxicity”.

HeriCare-Breast01 (NCT07377643) is a multicenter, randomized, open-label, active-controlled study designed to evaluate the safety and efficacy of IBI354, with or without pertuzumab, compared with the current standard-of-care, paclitaxel plus trastuzumab and pertuzumab (THP). The primary endpoint is progression-free survival (PFS).

Previously, in a multicenter Phase 1/2 study in participants with advanced solid tumors, a total of 88 participants with HER2-positive breast cancer were enrolled(the median prior treatment lines was 4) and were treated with 6-15 mg/kg doses of IBI354.

  • As of March 24, 2025, the overall confirmed objective response rate (cORR) was 59.1% and the disease control rate (DCR) was 90.9%.
  • Among them, ORR reached 72.4% and DCR reached 89.7% in 29 breast cancer participants treated with 9mg/kg Q3W.
  • The median follow-up time of 9mg/kg Q3W dose group was 13.6 months as of the cut-off date, and progression-free survival (PFS) was 14.1 month (95%CI: 8.3, NC). The data were presented at the ASCO 2025[Link].

IBI354 also demonstrated an excellent safety profile in this Phase 1/2 clinical study (n=368). 

  • No DLT was occurred up to 18mg/kg dose group.
  • The overall incidence of grade 3 or higher treatment-related adverse events (TRAEs) in 9mg/kg Q3W dose group was 21.0%, the incidence of TRAEs leading to dose interruption was 9.9%, the incidence of TRAEs leading to dose reduction was 1.2%, the overall incidence of TRAEs leading to discontinuation was 1.2%, and no TRAE leading to death reported.
  • The most common TRAEs are white blood cell count decreased, nausea and anemia. The incidence of interstitial lung disease was only 1.2%, all were grade 1.

The Principal Investigator of the HeriCare-Breast01 study, Binghe Xu, academician of the Chinese Academy of Engineering from Cancer Hospital Chinese Academy of Medical Sciences, stated, “We are pleased to complete the first patient enrollment for the HeriCare-Breast01 study at our center. Although first-line treatment for HER2-positive advanced breast cancer has improved substantially—with the THP regimen delivering durable responses for many patients—important clinical challenges remain. These include treatment discontinuation driven by toxicity and limited tolerability of currently available ADCs, particularly among older patients and those with comorbid conditions. As a next-generation HER2-targeted ADC, IBI354 has shown compelling antitumor activity in Phase 1/1b studies, achieving class-leading ORR and DCR, alongside a notably favorable safety profile. In particular, IBI354 has demonstrated reduced incidence of key adverse events such as interstitial lung disease (ILD), peripheral neuropathy, and neutropenia. This “high-efficacy, low-toxicity” therapeutic window may allow a broader range of patients to achieve sustained, high-quality treatment outcomes. We look forward to the Phase 3 HeriCare-Breast01 study to further validate this potential and advancing IBI354 toward becoming a new standard of care in the first-line treatment for HER2-positive advanced breast cancer. “

Dr. Zhou Hui, Chief R&D Officer (Oncology) of Innovent, stated, “The initiation of the pivotal Phase 3 HeriCare-Breast01 trial in China marks a significant milestone in the clinical translation of Innovent’s ADC pipeline. Leveraging the world’s leading antibody engineering and differentiated linker-payload technologies, Innovent has established a highly competitive and innovative TOPO1i ADC technology platform SoloTx®. IBI354 has demonstrated a compelling safety and efficacy profile in early-stage studies, strongly validating the strengths of our SoloTx® ADC platform. IBI354 holds strong potential to offer a new first-line treatment option for patients with HER2-positive advanced breast cancer—one that combines durable antitumor activity with favorable long-term tolerability. Looking ahead, Innovent will continue to advance innovation of next-generation IO+ADC, with a steadfast commitment to delivering improved therapeutic outcomes for cancer patients.”

About Breast Cancer

Breast cancer is one of the most common cancers among women worldwide. Approximately 1.3 million women are diagnosed with breast cancer each year, and about 30% of them develop locally advanced or metastatic breast cancer. The clinical proportion of HER2-positive breast cancer is approximately 20%[1]. Previous studies have demonstrated that overexpression of this HER2 gene plays a significant role in the occurrence and development of invasive breast cancer and is associated with an increased recurrence rate and poor prognosis [2]. At present, no ADC targeting HER2 has been fully approved for first-line treatment of advanced breast cancer in China. There is an urgent need for new drugs to improve the prognosis of patients.

About IBI354

IBI354 is an innovative HER2-targeted antibody–drug conjugate developed using Innovent’s proprietary SoloTx® ADC platform. Based on this platform, Innovent is promoting clinical trial studies multiple self-developed ADC molecules, which have shown promising safety and efficacy signals.

With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors.

Starting from the urgent clinical needs, in addition to the Phase 3 studies (HeriCare-Breast01 and HeriCare-Ovarian01) already initiated in BC and PROC, Innovent will explore IBI354 in multiple solid tumor indications.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Reference

[1] Breast Cancer Expert Committee of Chinese Society of Clinical Oncology, Breast Cancer Professional Committee of China Anti-Cancer Association. Expert Consensus on Clinical Diagnosis and Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (2021 version)[J]. National Medical Journal of China, 2021, 101(17): 1226-1231. DOI: 10.3760/cma.j.cn112137-20210318-00679.

[2] Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119-129. doi:10.1007/978-0-387-74039-3_9.

Cision View original content:https://www.prnewswire.com/news-releases/innovent-dosed-first-participant-in-phase-3-clinical-study-of-ibi354-novel-her2-adc-for-first-line-treatment-of-her2-positive-breast-cancer-302686402.html

SOURCE Innovent Biologics

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.08187
$0.08187$0.08187
-0.79%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Crucial Fed Rate Cut: Powell’s Bold Risk Management Move Explained

Crucial Fed Rate Cut: Powell’s Bold Risk Management Move Explained

BitcoinWorld Crucial Fed Rate Cut: Powell’s Bold Risk Management Move Explained In a significant development for global financial markets, Federal Reserve Chair Jerome Powell recently described the latest Fed rate cut as a critical risk management measure. This statement immediately captured the attention of investors, economists, and especially those in the dynamic cryptocurrency space. Understanding Powell’s rationale and the potential implications of this move is essential for navigating today’s complex economic landscape. What Exactly is a Fed Rate Cut and Why Does it Matter? A Fed rate cut refers to the Federal Reserve lowering the target range for the federal funds rate. This is the interest rate at which commercial banks borrow and lend their excess reserves to each other overnight. When the Fed lowers this rate, it typically makes borrowing cheaper across the entire economy. This decision impacts everything from mortgage rates to business loans. The Fed uses interest rates as a primary tool to influence economic activity, aiming to achieve maximum employment and stable prices. A lower rate often stimulates spending and investment, but it can also signal concerns about economic slowdown. Key reasons for a rate cut often include: Slowing economic growth or recession fears. Low inflation or deflationary pressures. Global economic instability impacting domestic markets. A desire to provide more liquidity to the financial system. Powell’s emphasis on ‘risk management’ suggests a proactive approach. The Fed is not just reacting to current data but also anticipating potential future challenges. They are essentially trying to prevent a worse economic outcome by adjusting policy now. How Does a Fed Rate Cut Influence the Broader Economy? When the Federal Reserve implements a Fed rate cut, it sends ripples throughout the financial world. For traditional markets, lower interest rates generally mean: Boost for Stocks: Companies can borrow more cheaply, potentially increasing profits and stock valuations. Investors might also move money from lower-yielding bonds into equities. Cheaper Borrowing: Consumers and businesses enjoy lower rates on loans, from mortgages to credit cards, encouraging spending and investment. Weaker Dollar: Lower rates can make a country’s currency less attractive to foreign investors, potentially leading to a weaker dollar. Bond Market Shifts: Existing bonds with higher yields become more attractive, while newly issued bonds will have lower yields. This shift in monetary policy aims to inject confidence and liquidity into the system, countering potential economic headwinds. However, there’s always a delicate balance to strike, as too much stimulus can lead to inflationary pressures down the line. What Does This Fed Rate Cut Mean for Cryptocurrency Investors? The impact of a Fed rate cut on the cryptocurrency market is often a topic of intense discussion. While crypto assets operate independently of central banks, they are not immune to broader macroeconomic forces. Here’s how a rate cut can play out: Increased Risk Appetite: With traditional savings and bond yields potentially lower, investors might seek higher returns in riskier assets, including cryptocurrencies like Bitcoin and Ethereum. Inflation Hedge Narrative: Some view cryptocurrencies, particularly Bitcoin, as a hedge against inflation and traditional currency debasement. If a rate cut leads to concerns about inflation, this narrative could gain traction. Liquidity Influx: A more accommodative monetary policy can increase overall liquidity in the financial system, some of which may flow into digital assets. Dollar Weakness: A weaker dollar, a potential consequence of rate cuts, can sometimes make dollar-denominated assets like crypto more appealing to international investors. However, it’s crucial to remember that the crypto market also has its unique drivers, including technological developments, regulatory news, and market sentiment. While a Fed rate cut can provide a tailwind, it’s not the sole determinant of crypto performance. Navigating the New Landscape: Actionable Insights for Crypto Investors Given the Federal Reserve’s stance on risk management through a Fed rate cut, what steps can crypto investors consider? Stay Informed: Keep a close watch on further Fed announcements and economic data. Understanding the broader macroeconomic picture is vital. Diversify Your Portfolio: While a rate cut might favor risk assets, a balanced portfolio that includes a mix of traditional and digital assets can help mitigate volatility. Long-Term Perspective: Focus on the fundamental value and long-term potential of your chosen cryptocurrencies rather than short-term fluctuations driven by macro news. Assess Risk Tolerance: Re-evaluate your personal risk tolerance in light of potential market shifts. Lower rates can encourage speculation, but prudence remains key. Powell’s description of the Fed rate cut as a risk management measure highlights the central bank’s commitment to maintaining economic stability. For cryptocurrency enthusiasts, this move underscores the increasing interconnectedness of traditional finance and the digital asset world. While a rate cut can create opportunities, a thoughtful and informed approach is always the best strategy. Frequently Asked Questions (FAQs) What exactly is a Fed rate cut? A Fed rate cut is when the Federal Reserve lowers its target for the federal funds rate, which is the benchmark interest rate banks charge each other for overnight lending. This action makes borrowing cheaper across the economy, aiming to stimulate economic activity. Why did Powell emphasize “risk management” for this Fed rate cut? Jerome Powell emphasized “risk management” to indicate that the Fed was proactively addressing potential economic slowdowns or other future challenges. It suggests a preventative measure to safeguard against adverse economic conditions rather than merely reacting to existing problems. How does a Fed rate cut typically affect the crypto market? A Fed rate cut can make traditional investments less attractive due to lower yields, potentially driving investors towards higher-risk, higher-reward assets like cryptocurrencies. It can also increase overall market liquidity and strengthen the narrative of crypto as an inflation hedge. Should crypto investors change their strategy after a rate cut? While a rate cut can influence market dynamics, crypto investors should primarily focus on their long-term strategy, fundamental research, and risk tolerance. It’s wise to stay informed about macroeconomic trends but avoid making impulsive decisions based solely on a single policy change. What are the potential downsides of a Fed rate cut? Potential downsides include increased inflationary pressures if the economy overheats, a weaker national currency, and the possibility of creating asset bubbles as investors chase higher returns in riskier markets. It can also signal underlying concerns about economic health. Did you find this article insightful? Share your thoughts and help others understand the implications of the Fed’s latest move! Follow us on social media for more real-time updates and expert analysis. To learn more about the latest crypto market trends, explore our article on key developments shaping Bitcoin’s price action. This post Crucial Fed Rate Cut: Powell’s Bold Risk Management Move Explained first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 16:40
Inference Research Launches in Hong Kong with US$20M Seed Funding

Inference Research Launches in Hong Kong with US$20M Seed Funding

Inference Research, an AI-native quantitative trading firm based in Hong Kong, has announced its launch and the expected closing of a US$20 million Seed funding
Share
Fintechnews2026/02/13 11:38
Should traders track FLOKI, memecoins to see where Bitcoin’s price will go?

Should traders track FLOKI, memecoins to see where Bitcoin’s price will go?

The post Should traders track FLOKI, memecoins to see where Bitcoin’s price will go? appeared on BitcoinEthereumNews.com. The memecoin sector, characterized by
Share
BitcoinEthereumNews2026/02/13 11:15